Table II.

B:T and IL-4: IFN-γ ratios in thyroids of BALB/c and nonobese diabetics recipients of TSHR primed T cells

TreatmentaBALB/cNonobese Diabetic
ThyroiditisbB:T cell ratiocIL-4:IFN-γ ratiodThyroiditisbB:T cell ratiocIL-4:IFN-γ ratiod
0.81.32+0.350.12
Examined 8 wk post receipt of whole MBP-ECD primed T cells0.91.43+0.320.1
+1.21.98+0.280.09
+1.320.410.13
+1.32.12+0.290.09
+1.72.99+0.30.09
+1.83.18+0.420.12
+1.83.09
+1.93.22
+1.93.41
Examined 8 wk postreceipt MBP-ECD CD4+ T cells0.81.33+0.280.09
+1.21.93+0.290.1
+1.21.84+0.30.11
+1.82.53+0.350.11
+1.92.61+0.330.1
Examined 12 wk postreceipt MBP-ECD whole T cells+1.63+0.240.08
+1.73.26+0.260.1
+1.73.41+0.28.09
+1.83.42
+1.93.5
  • a Treatments are as follows: 8 wk whole T, mice examined 8 wk after transfer of T cells primed with the extracellular domain of the TSHR fusion protein and not fractionated; 8 wk CD4+, mice examined 8 wk after transfer of T cells primed with the extracellular domain of the TSHR fusion protein and fractionated to yield CD4+ enriched; 12 wk whole T, mice examined 12 wk after transfer of T cells primed with the extracellular domain of the TSHR fusion protein and not fractionated.

  • b −, absence of thyroiditis; +, presence of thyroiditis.

  • c The numbers of intrathyroidal CD3+ T cells and B cells in BALB/c mice were evaluated at a magnification of ×250 in 10 microscopic fields chosen at random and given as the B:T cell ratio.

  • d The numbers of IL-4 and IFN-γ-positive cells were enumerated in the same way and the results expressed as a ratio.